Matching articles for "Vulvovaginal atrophy"
Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia
The Medical Letter on Drugs and Therapeutics • September 10, 2018; (Issue 1555)
The FDA has approved an estradiol softgel vaginal
insert (Imvexxy – TherapeuticsMD) for treatment of
postmenopausal women with moderate to severe
dyspareunia due to vulvovaginal atrophy (VVA).
Imvexxy is...
The FDA has approved an estradiol softgel vaginal
insert (Imvexxy – TherapeuticsMD) for treatment of
postmenopausal women with moderate to severe
dyspareunia due to vulvovaginal atrophy (VVA).
Imvexxy is the second estradiol vaginal insert to be
approved in the US; Vagifem, an intravaginal tablet
formulation, was the first. Vagifem and Imvexxy are
both available in inserts containing 10 mcg of estradiol;
Imvexxy is also available in a 4-mcg strength.
Prasterone (Intrarosa) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • September 11, 2017; (Issue 1529)
The FDA has approved the steroid prasterone
(Intrarosa – Endoceutics) for intravaginal treatment
of postmenopausal women with moderate-to-severe
dyspareunia due to vulvovaginal atrophy (VVA). Also
called...
The FDA has approved the steroid prasterone
(Intrarosa – Endoceutics) for intravaginal treatment
of postmenopausal women with moderate-to-severe
dyspareunia due to vulvovaginal atrophy (VVA). Also
called dehydroepiandrosterone (DHEA), prasterone
is produced in the adrenal glands, gonads, and brain
and converted intracellularly into active metabolites
of estrogens and androgens. DHEA has been available
over the counter for years as an oral dietary supplement
claimed to benefit sexual, cardiovascular, and
neuropsychiatric dysfunction.
Ospemifene (Osphena) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • July 8, 2013; (Issue 1420)
The FDA has approved ospemifene (os pem’ i feen;
Osphena – Shionogi), an estrogen agonist/antagonist,
for oral treatment of moderate to severe dyspareunia in
postmenopausal women. Ospemifene is the...
The FDA has approved ospemifene (os pem’ i feen;
Osphena – Shionogi), an estrogen agonist/antagonist,
for oral treatment of moderate to severe dyspareunia in
postmenopausal women. Ospemifene is the fourth estrogen
agonist/antagonist to be marketed in the US, but it is
the only one that has an estrogen-like effect on vaginal
epithelium. The other three, tamoxifen (Nolvadex, and
generics), toremifene (Fareston), and raloxifene (Evista),
are used for treatment and prevention of breast cancer
and osteoporosis.
Conjugated Estrogens (Premarin) Vaginal Cream
The Medical Letter on Drugs and Therapeutics • February 23, 2009; (Issue 1306)
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy...
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.